|
gptkbp:instanceOf
|
antiviral drug
HIV fusion inhibitor
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AX07
|
|
gptkbp:brand
|
gptkb:Fuzeon
|
|
gptkbp:CASNumber
|
159519-65-0
|
|
gptkbp:developedBy
|
gptkb:Roche
gptkb:Trimeris
|
|
gptkbp:drugClass
|
antiretroviral therapy
|
|
gptkbp:eliminationHalfLife
|
3.8 hours
|
|
gptkbp:excretion
|
kidney (minor)
|
|
gptkbp:hasMolecularFormula
|
C204H301N51O64
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
enfuvirtide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits fusion of HIV-1 with CD4+ cells
|
|
gptkbp:metabolism
|
catabolism
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:proteinOrPeptide
|
yes
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
injection site reaction
hypersensitivity
bacterial pneumonia
|
|
gptkbp:synonym
|
gptkb:T-20
|
|
gptkbp:target
|
gptkb:gp41_protein_of_HIV-1
|
|
gptkbp:UNII
|
Q1J8A4N3SG
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:HIV_entry_inhibitors
gptkb:Fuzeon
|
|
gptkbp:bfsLayer
|
7
|